Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04596618
Other study ID # H20-0092
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 20, 2020
Est. completion date December 9, 2020

Study information

Verified date December 2020
Source University of Connecticut
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of intermittent forearm cooling on exercise performance in the heat.


Description:

The study will be completed in the following timeline: Visit 1: Baseline and VO2max testing. Visit 2-3: Trial 1 and 2 Visit specific information is described below, however, specific data collection protocols for dependent variables and procedures are included below the description of the study design. Visit 1: Baseline and VO2max Testing Participants who are approved to participate will be scheduled for a baseline and VO2max testing day. Upon arrival to the lab, subjects will provide a urine sample in a clean urine cup. Urine specific gravity and urine color will be assessed. Nude body mass will be also be recorded. Privacy will be afforded for each participant while obtaining body mass measures by taking measurements with the participant alone in a private room behind a solid, closed door, and the research reading the scale outside of the room. Participants will only be permitted to continue to the VO2max test if the euhydrated criteria of a urine specific gravity (USG) <1.025 is met. If the participant arrives with a USG between 1.020 and 1.025, the subject will be asked to drink 500 mL of water to ensure proper hydration status. Height will be measured with a tape measure on Visit 1. Percent body fat will be calculated using a 3-site evaluation of skin fold thickness using skin fold calipers. A researcher will use appropriate grasping technique to measure skin fold thickness on the chest, tricep, and abdomen. This will take less than 5 minutes to complete. This information will be used to describe the subject demographics. Participants will also be asked to complete a maximal oxygen uptake (VO2max) test on a treadmill in a thermoneutral environment. This test will provide aerobic fitness levels of the participants. This visit will take approximately 1-2 hours. Visit 2-3: Trials 1 and 2 Participant numbers will be randomly assigned, and trials will be ordered with a random number generator and assigned to a participant number. These orders will be counterbalanced between participants to ensure that there is not an order effect, and each participant will complete two trials as part of the study. Participants will be allowed to make-up trial visits if they are sick, suffer an injury or do not meet hydration requirements. Participants will be asked if they have a current illness or taking medications to determine whether they can complete the exercise trial. The participant's visit will be rescheduled if they have a fever, current illness or taking medications that influence body temperature. Participants will complete two trials on two separate days in a randomized counter balanced order: Trial Cooling Intervention 1. Passive Cooling 2. Forearm Immersion The exercise protocol, cooling intervention, and performance battery portions of this study will be conducted in a climatic chamber with ambient temperature approximately 30-40C and relative humidity at approximately 40-60%. Participants will drink approximately 1.4L of water throughout the exercise trial. Upon arrival to the lab, participants will be asked to indicate if they have consumed alcohol or caffeine in the last 24 hours and 12 hours, respectively. They will not be asked to specify exactly what they have consumed, but if they provide a positive indication, their trial will be rescheduled for another day. Participants will provide a small urine sample in a clean urine cup, and a nude body mass will be measured. Upon arrival to the lab, hydration status will be assessed by urine specific gravity, nude body mass and urine color. Participants will only be permitted to continue to the exercise trial if the euhydrated criteria of a urine specific gravity (USG) <1.025 is met. If the participant arrives with a USG between 1.020 and 1.025, the subject will be asked to drink 500 mL of water to ensure proper hydration status. Participants will be given instructions at the prior visit about how to obtain desired hydration status for the upcoming trial. Participants will insert a rectal probe and wear a heart rate monitor strap. Researchers will insert the esophageal probe. Additionally, participants will wear 4-site skin temperature sensors. Researchers will apply the skin temperature sensors with medical tape to the participants' chest, upper arm, thigh, and calf. Participants will enter the environmental chamber and sit for 10 minutes to become equilibrated. Participants will wear a metabolic mask during this time to assess baseline metabolic heat production. The environmental chamber will be set to 35C ambient temperature, 50% relative humidity. After baseline measures of heart rate, rectal temperature, and metabolic heat production, participants will complete the perceptual indices. Participants will also complete an environmental symptoms questionnaire (ESQ). The trial will consist of three, 20-minute exercise bouts consisting of walking, running, and sprinting at varying speeds ranging approximately 20-90% of their VO2max. Followed by a 12-minute "half-time" consisting of passive rest. Participants will then complete three more 20-minute exercise bouts consisting of walking, running, and sprinting at varying speeds ranging approximately 20-90% of their VO2max, for a total of six 20-minute bouts. Each 20-minute exercise bout with be followed by a 3-minute break where cooling will occur. Participants will be allowed to drink 750mL of water throughout each exercise half for a total of 1.4L. The participant will be cooled for approximately 3 minutes after each 20-minute exercise bout with their assigned cooling modality. Rectal temperature, esophageal temperature, skin temperature, heart rate, perceptual measures, and metabolic heat production will be collected at various time points before, during, and after exercise and cooling. Following the completion of the six 20-minute exercise bouts, participants will perform the performance battery. The performance battery will consist of an agility test, grip strength test, broad-jump test, sprint test, and 1-mile time trial test. Passive Cooling: Participants will be asked to sit in a chair in the climate chamber for passive cooling. Forearm immersion: The participant will place both of their forearms in approximately 15C water during forearm immersion. Each trial will be approximately 3 hours. All devices will be properly cleaned according to manufacturer's instruction prior to use by other participants.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 9, 2020
Est. primary completion date December 9, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Cisgender male between the ages of 18-30 years - been cleared by the medical monitor for the study - VO2max >45ml/kg/min Exclusion Criteria: - 1. have a current musculoskeletal injury that would limit their physical activity or preclude the participant from walking, jogging, running, sprinting, or cutting. 2. Chronic health problems that affect your ability to thermoregulate (disorders affecting the liver, kidneys or the ability to sweat normally) 3. Fever or current illness at the time of testing 4. History of cardiovascular, metabolic, or respiratory disease 5. Current musculoskeletal injury that limits their physical activity 6. Currently taking a medication that is known to influence body temperature (amphetamines, antihypertensives, anticholinergics, acetaminophen, NSAIDs, aspirin) 7. Are a female 8. Have a history of heat related illness 9. Have any cold allergies or adverse reactions to the cold (i.e. cold urticaria, Raynaud's, cryoglobulinemia)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Forearm cooling
forearm cooling will be performed for active cooling assessment.

Locations

Country Name City State
United States Gampel Pavilion Storrs Connecticut

Sponsors (1)

Lead Sponsor Collaborator
University of Connecticut

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Rectal Temperature Rectal thermometer will be self-inserted by participant to assess core temperature Measured continuously during the duration of the trial (total 150 minutes)
Primary Change in Mean Skin Temperature 4 skin temperature sensors will be placed on the subject (chest, shoulder, thigh, calf) Measured continuously during the duration of the trial (total 150 minutes)
Primary Change in Heart Rate A heart rate monitor will be worn by participant throughout exercise/cooling protocol Measured continuously during the duration of the trial (total 150 minutes)
Primary Change in Esophageal Temperature An esophageal thermometer will be inserted by the researchers to assess participants esophageal temperature. Measured continuously during the duration of the trial (total 150 minutes)
Primary Change in Rating of Perceived Exertion (RPE) 6-20 scale that indicates how hard the participant feels they are working. 6 represents rest and 20 represents maximal exertion. A high score indicates more perceived exertion. Measured every 5 minutes during the duration of the trial (total 150 minutes)
Primary Change in Thermal Sensation (TS) 0-8 Scale (cold to hot) that indicated how cold or hot the participate feels. 0 = extremely cold, 8 = extremely hot. Measured every 5 minutes during the duration of the trial (total 150 minutes)
Primary Change in Perception of Fatigue 0-10 (no fatigue to extreme fatigue) Scale that indicates how fatigued the participate feels. High score indicates more fatigue (negative outcome). Measured every 5 minutes during the duration of the trial (total 150 minutes)
Primary Change in Perception of Thirst 0-9 (no thirst to extreme thirst) Scale that indicates how thirsty the subject feels. A higher score is considered a negative outcome. Measured every 5 minutes during the duration of the trial (total 150 minutes)
Primary Environmental Symptoms An environmental symptoms questionnaire to indicate they feel (hot, lethargic, irritable) with the scale ranging from Not at all, a little, somewhat, moderate, a lot, to extreme. Before the start of exercise block 1
Primary Environmental Symptoms An environmental symptoms questionnaire to indicate they feel (hot, lethargic, irritable) with the scale ranging from Not at all, a little, somewhat, moderate, a lot, to extreme. After completion of the performance battery, at time point 180min.
Primary Quick-Board Agility Agility will be assessed by number of foot taps within 10seconds and then number of hops within 10seconds. After the end of 3min cooling period block 6
Primary Broad Jump Participants will attempt to jump as far forward as they can 3 times, measured in centimeters. after the quick-board agility, at time point 153minutes
Primary Grip Strength Participants will squeeze a hand held dynamometer 3 times, measured in kilograms after the Broad jump test, at time point 155minutes
Primary Sprints On a non-motorized treadmill, participants will sprint for 6sec followed by 24sec of rest, repeat 3 times, belt revolutions will be measured. after the grip strength test, at time point 160minutes
Primary One Mile Timed Trial On a motorized treadmill, participants will run at a self-selected pace until they run a distance of 1-mile, time measured in minutes after the sprint test, at time point 170minutes
Primary Metabolic heat production Using a metabolic mask and metabolic cart, metabolic heat production will be collected. Measured during the last 5 minutes of each exercise block for a total of six measurements for a total of 36minutes.
See also
  Status Clinical Trial Phase
Completed NCT04431596 - Military Alerting System for Monitoring Body Temperature During Active Cooling N/A
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT00940654 - The Fever and Antipyretic in Critically Illness Evaluation Study N/A
Recruiting NCT05809453 - Intranasal Cocaine and Temperature Regulation During Exercise Phase 1/Phase 2
Completed NCT04915859 - Semiconductor Heat Extraction Cooling N/A
Completed NCT04613843 - Cold Water Immersion Stirring in Hyperthermic Individuals N/A
Completed NCT03689478 - Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT N/A
Completed NCT02271607 - The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients N/A
Terminated NCT01963117 - Effectiveness of the Combined WLI and Hyperthermia for GI Cancer Liver Metastasis N/A
Withdrawn NCT05710978 - Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain N/A
Completed NCT05586477 - Diphenhydramine and Sweating Phase 4
Completed NCT01576822 - Sauna Detoxification Study: Pilot Feasibility Phase 1
Recruiting NCT05366270 - Peripheral Neuroimmune Mechanisms of Hyperthermia N/A
Recruiting NCT05993910 - Prospective Hyperthermia Database in Cancer Patients (HT Register)
Terminated NCT04104334 - Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC N/A
Not yet recruiting NCT06389604 - Preparing for Heat Waves - Enhancing Human Thermophysiological Resilience N/A
Not yet recruiting NCT05274009 - Protective Cooling Measures to Safeguard Elderly People From Dangerous Summer Heat N/A
Terminated NCT00796900 - Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH) Phase 2/Phase 3
Not yet recruiting NCT06278883 - Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase N/A
Active, not recruiting NCT02546596 - The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer N/A